SynAct Pharma Signs First Commercial Partner for Resomelagon
SynAct Pharma has signed a 50/50 commercial partnership for resomelagon.
Story updates
09:44:54 AM UTC
SquawkNews
SynAct Pharma signed a 50/50 co-development and commercialization agreement with Hipolabor covering dengue in Brazil, marking resomelagon’s first commercial partnership. SynAct retains full asset control and flexibility for other indications and regions.Material DetailsContext by AI AnalystThis is…